EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 22.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immun...
Source: boersennews.de